The Pulse
The FDA's 503B comment window closes June 29.
Less than four weeks remain on the public comment period for the FDA's proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List.
If the rule finalizes, outsourcing facilities lose the bulk-compounding pathway for GLP-1s. The 503A individualized-script route survives, but cannot be used to mass-produce identical copies of the brand drug, only true individualized formulations with documented medical necessity.
Brands still leaning on compounded supply have less than a month to lock the patient communication plan that goes with a transition, before the news writes that story for them.
UHS pays $835M for Talkspace.
Universal Health Services acquired Talkspace for $835M, one of the largest virtual-mental-health deals on record. Q1 digital health M&A volume was up 47% versus Q4, with 56 deals closed.
The signal for telehealth operators is the category convergence. Traditional health systems and PE-backed consolidators are paying real money to treat virtual care as infrastructure, not as a feature. The brands that win the next 18 months will be category-defining or category-acquired, with fewer in between.
Hims posts a Q1 loss and adds 8 Benefits partners in the same month.
Hims reported Q1 revenue of $608M (+4% YoY) and a $92M net loss, both driven by the wind-down of compounded weight-loss SKUs. Subscribers reached 2.6M. Full-year guidance was raised to $2.8-3B.
On May 28, Hims added 8 brands to its subscriber Benefits program: Natural Cycles, MyFitnessPal, Ladder, PVOLVE, HelloFresh, Factor, Flo Health, Dexcom, and iFIT.
The Q1 print took the hit. The Benefits build is what the hit was paying for. More on what that signals below.
The Deep Dive
Hims just signaled where telehealth retention is heading.
The Benefits announcement reads like a brand-collab press release. It is not. It is a retention defense built in public, on the same week the company posted a $92M loss.
Three things are happening underneath the news.
1. The medication is becoming a commodity.
Foundayo (oral GLP-1) is shipping. Lilly is selling direct through LillyDirect. Amazon One Medical launched GLP-1 care in April. Generic semaglutide is on the table in multiple geographies, with a Hims Canada launch this month.
The prescription itself, the thing most telehealth subscriptions are built around, is being commoditized faster than most retention systems can adjust.
When the medication is the only reason a patient stays, the patient will move the day a cheaper or more convenient option appears.
2. The retention currency is shifting from emails to ecosystem.
Most retention work right now is internal: better save flows, better win-back, better cancellation reasons, better deliverability. Those are the right fights. They are not the only fight.
Hims just stacked roughly $400 in outside benefits onto every active subscriber:
11 free HelloFresh meals
3 free months of iFIT
28 days of Natural Cycles
50% off the first Factor box plus a year of free breakfast items
15% off MyFitnessPal Premium+
Access to Dexcom's Stelo continuous glucose monitor
Discounted Flo Health, Ladder, and PVOLVE access
100% of the negotiated value is passed through to the subscriber. Hims is not skimming partnership margin.
The point is not partner revenue. The point is making the membership worth more outside of the prescription itself. A patient who cancels Hims now also walks away from a benefits stack their cheaper alternative cannot match.
3. Smaller brands cannot match the deal flow. They can copy the principle.
Most readers of this newsletter cannot negotiate a Dexcom partnership at $5-50M ARR. That is fine. The defensive principle scales down:
Free quarterly provider check-ins for patients past month three, using idle clinical capacity
A branded education library or app-only content that patients lose access to on cancel
Community access (Skool, Discord, private group) that the prescription alone does not get them into
Curated supplement or wellness affiliate gift cards as tenure milestones, no fulfillment overhead
Bundled labs at month 3, 6, 12, operationally cheap, perceived as premium
None of these are new ideas in isolation. The shift is treating them as the retention strategy, not as nice-to-have flow content.
The patient should be able to point to specific things they get from the subscription that they cannot get for free anywhere else inside 60 days.
The takeaway. Audit your subscription this week. If the line items are the prescription, the consult, and the refills, that is not a subscription. That is a recurring transaction with a cancel button. The brands that survive the next 18 months will be the ones that turned the membership into something worth keeping when the meds themselves are no longer a moat.
Quick Takes
The 503B window is also your retention window.
The next four weeks of patient communication matter more than any single email you have ever sent.
If the rule finalizes and your brand still uses compounded supply, patients will hear about it from the news before they hear it from you, and they will cancel before they ask.
Front-load the messaging now: what changes, what does not, and what their continuity plan looks like.
Talkspace at $835M is the category-infrastructure floor.
Virtual mental health is not a feature anymore. It is part of the baseline that health systems and PE are paying real money for.
If your telehealth brand has no clear answer for whether mental health is part of your offering, your partnership stack, or explicitly out of scope, that answer is going to get picked for you inside 12 months.
One Thing to Try
Open a doc. Write down every concrete thing a patient gets when they pay you this month.
Not the marketing of it, the actual line items: the prescription, the consult, the refill, the message access, the portal, the welcome PDF, the everything.
Now mark each one for whether the patient could get the same thing for free, cheaper, or more conveniently somewhere else inside 60 days.
If every line is a yes, your retention problem is not in your emails. It is in your value stack.
Pick one item to add this week, even a small one. A monthly group call. An invite-only Q&A with the provider. A curated reading list. A referral credit. Make the membership do more work than the medication.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.